BioticsAI received FDA clearance for software that helps detect fetal abnormalities in ultrasound images, TechCrunch reported on January 19th. The company, winner of TechCrunch Disrupt's 2023 Battlefield competition, says its computer vision system supports fetal ultrasound quality assessment, anatomical completeness, automated reporting, and integration into clinical workflows. Founder Robhy Bustami told TechCrunch that the harder task was proving reliability outside ideal cases, including across patient subgroups with higher risk.

The prenatal screen places machine vision inside one of medicine's most charged images. An ultrasound is already a strange document, part clinical evidence and part family apparition, read by specialists while parents search the blur for reassurance. Adding AI changes the authority around that blur. The system does not replace the scan; it judges whether the scan is complete enough, whether anatomy has been seen, and whether a possible abnormality deserves attention. That can help in clinics where skill, time, and access are uneven. It also makes prenatal care depend on a second reader whose confidence must survive bodies, demographics, equipment, and poor images. Before a child has a name, the image may already have passed through a regulatory file and a model trained to decide what the eye might miss.